
Posted Feb 3, 2021 12:47 am MST
Final Up to date Feb 3, 2021 at 1:00 am MST
LONDON — U.Okay.-based drugmaker GlaxoSmithKline and Germany’s CureVac say they plan to collaborate on a brand new era of vaccines focusing on rising variants of COVID-19.
The announcement comes as public well being consultants around the globe increase considerations about mutations within the virus that will make current vaccines much less efficient.
“The rise in rising variants with the potential to cut back the efficacy of first era COVID-19 vaccines requires acceleration of efforts to develop vaccines towards new variants to maintain one step forward of the pandemic,’’ the businesses stated in a press release Wednesday. “These subsequent era COVID-19 vaccines could both be used to guard individuals who haven’t been vaccinated earlier than, or to function boosters within the occasion that COVID-19 immunity gained from an preliminary vaccination reduces over time.”
GSK says it should additionally assist CureVac manufacture as much as 100 million doses of its current vaccine candidate this yr.
___
Observe all of AP’s pandemic protection at https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak
The Related Press
{* mergeAccounts *}